Preventing chemoresistance of human breast cancer cell line, MCF-7 with celecoxib

[1]  R. Farinotti,et al.  Cyclooxygenase Inhibitors Down Regulate P-glycoprotein in Human Colorectal Caco-2 Cell Line , 2008, Pharmaceutical Research.

[2]  Y. Yun,et al.  Radiosensitivity enhancement by celecoxib, a cyclooxygenase (COX)-2 selective inhibitor, via COX-2-dependent cell cycle regulation on human cancer cells expressing differential COX-2 levels. , 2005, Cancer research.

[3]  Soo-Jeong Lim,et al.  Cyclooxygenase-independent down-regulation of multidrug resistance–associated protein-1 expression by celecoxib in human lung cancer cells , 2005, Molecular Cancer Therapeutics.

[4]  D. Reinhardt,et al.  Impact of the Cyclooxygenase System on Doxorubicin-Induced Functional Multidrug Resistance 1 Overexpression and Doxorubicin Sensitivity in Acute Myeloid Leukemic HL-60 Cells , 2005, Journal of Pharmacology and Experimental Therapeutics.

[5]  A. Goda,et al.  The potential role of cyclooxygenase-2 inhibitors in the treatment of experimentally-induced mammary tumour: does celecoxib enhance the anti-tumour activity of doxorubicin? , 2004, Pharmacological research.

[6]  H. Fu,et al.  Promoter hypermethylation silences cyclooxygenase-2 (Cox-2) and regulates growth of human hepatocellular carcinoma cells , 2004, Laboratory Investigation.

[7]  T. Oberyszyn,et al.  Treatment with 5-fluorouracil and celecoxib displays synergistic regression of ultraviolet light B-induced skin tumors. , 2004, The Journal of investigative dermatology.

[8]  F. Cianchi,et al.  Cyclooxygenase-2 Activation Mediates the Proangiogenic Effect of Nitric Oxide in Colorectal Cancer , 2004, Clinical Cancer Research.

[9]  R. Komaki,et al.  Improvement strategies for molecular targeting: Cyclooxygenase-2 inhibitors as radiosensitizers for non-small cell lung cancer. , 2004, Seminars in oncology.

[10]  A. Sorokin.  Cyclooxygenase-2: potential role in regulation of drug efflux and multidrug resistance phenotype. , 2004, Current pharmaceutical design.

[11]  K. Subbaramaiah,et al.  Targeting cyclooxygenase-2 in human neoplasia: rationale and promise. , 2003, Cancer cell.

[12]  M. Gandelman.  Celecoxib: a selective cyclooxygenase-2 inhibitor , 2003, Arthritis Research & Therapy.

[13]  C. Stevens,et al.  Combination of a COX-2 Inhibitor With Radiotherapy or Radiochemotherapy in the Treatment of Thoracic Cancer , 2003, American journal of clinical oncology.

[14]  D. Yankelevitz,et al.  Celecoxib, a selective cyclo-oxygenase-2 inhibitor, enhances the response to preoperative paclitaxel and carboplatin in early-stage non-small-cell lung cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  T. Hla,et al.  Cyclooxygenase‐2 modulates cellular growth and promotes tumorigenesis , 2003, Journal of cellular and molecular medicine.

[16]  R. Clarke,et al.  ATP binding cassette transporters and drug resistance in breast cancer. , 2003, Endocrine-related cancer.

[17]  Marianne Fillet,et al.  NF-κB transcription factor induces drug resistance through MDR1 expression in cancer cells , 2003, Oncogene.

[18]  D. Rigal,et al.  Transcriptional regulators of the human multidrug resistance 1 gene: recent views. , 2002, Biochemical pharmacology.

[19]  A. Vannacci,et al.  The MDR phenotype is associated with the expression of COX‐2 and iNOS in a human hepatocellular carcinoma cell line , 2002, Hepatology.

[20]  W. Dalton,et al.  Cell adhesion is a key determinant in de novo multidrug resistance (MDR): new targets for the prevention of acquired MDR. , 2001, Molecular cancer therapeutics.

[21]  Gerd Geisslinger,et al.  Cyclooxygenase‐independent actions of cyclooxygenase inhibitors , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[22]  S. Grösch,et al.  Inhibition of NF‐ κ B and AP‐1 activation by R‐ and S‐flurbiprofen 1 2 , 2001 .

[23]  L. Ratner,et al.  Multidrug resistance transporters and modulation , 2000, Current opinion in oncology.

[24]  M J Dunn,et al.  Cyclooxygenase-2 Expression Inhibits Trophic Withdrawal Apoptosis in Nerve Growth Factor-differentiated PC12 Cells* , 2000, The Journal of Biological Chemistry.

[25]  H. Ciolino,et al.  Increased AP-1 activity in drug resistant human breast cancer MCF-7 cells , 1999, Breast Cancer Research and Treatment.

[26]  E. Zandi,et al.  AP-1 function and regulation. , 1997, Current opinion in cell biology.

[27]  S. H. Lee,et al.  Effect of the activated Raf protein kinase on the human multidrug resistance 1 (MDR1) gene promoter. , 1996, Cancer letters.

[28]  V. V. van Hinsbergh,et al.  Celecoxib enhances doxorubicin-induced cytotoxicity in MDA-MB231 cells by NF-kappaB-mediated increase of intracellular doxorubicin accumulation. , 2007, European journal of cancer.

[29]  B. Sikic,et al.  CCAAT/enhancer-binding protein beta (nuclear factor for interleukin 6) transactivates the human MDR1 gene by interaction with an inverted CCAAT box in human cancer cells. , 2004, Molecular Pharmacology.

[30]  B. Sikic,et al.  CCAAT/Enhancer-Binding Protein (cid:1) (Nuclear Factor for Interleukin 6) Transactivates the Human MDR 1 Gene by Interaction with an Inverted CCAAT Box in Human Cancer Cells , 2004 .

[31]  S. Grösch,et al.  Inhibition of NF-kappaB and AP-1 activation by R- and S-flurbiprofen. , 2001, The FASEB Journal.